p190-Bcr-Abl慢性髓性白血病的特征揭示特异性信号通路与治疗靶点
该研究采用下一代测序、磷酸化蛋白质组分析和药物敏感性检测,在CML患者及造血祖细胞系模型中表征p190-Bcr-Abl。p190-Bcr-Abl CML患者对伊马替尼反应差且表观遗传修饰基因突变频繁,其转录上调干扰素、IL-1受体和P53信号通路,并伴有JAK1/STAT1、PAK1及Src过度磷酸化。药物筛选发现IAP、PAK1、Src抑制剂和糖皮质激素在p190-Bcr-Abl细胞系中具有特异性活性。
要点
- p190-Bcr-Abl CML患者对伊马替尼反应差,表观遗传修饰基因突变频繁。
- p190-Bcr-Abl上调干扰素、IL-1受体和P53信号通路,伴JAK1/STAT1、PAK1及Src过度磷酸化。
- IAP、PAK1、Src抑制剂和糖皮质激素在p190-Bcr-Abl细胞系中显示特异性活性。
核心结论
- p190-Bcr-Abl CML具有独特的转录和磷酸化信号特征,对伊马替尼反应差,IAP、PAK1、Src抑制剂和糖皮质激素是潜在靶向治疗药物。
研究设计与样本
- 研究采用下一代测序、磷酸化蛋白质组分析和药物敏感性检测,对象为p190-Bcr-Abl CML患者及造血祖细胞系模型(Ba/f3和HPC-LSK)。
主要发现
- p190-Bcr-Abl CML患者对伊马替尼反应差且表观遗传修饰基因突变频繁。
- p190-Bcr-Abl特异性转录上调干扰素、白细胞介素-1受体和P53信号通路。
- p190-Bcr-Abl伴有JAK1/STAT1、PAK1及Src信号分子过度磷酸化。
- p190-Bcr-Abl细胞系显示与患者相似的转录和磷酸化信号特征。
关键数值与推荐
- 药物敏感性筛选鉴定出IAP抑制剂、PAK1抑制剂、Src抑制剂和糖皮质激素在p190-Bcr-Abl细胞系中具有特异性活性。
临床怎么用
- p190-Bcr-Abl CML患者可能对伊马替尼反应不佳,应考虑IAP、PAK1、Src抑制剂或糖皮质激素等靶向治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The oncogenic protein Bcr-Abl has two major isoforms, p190Bcr-Abl and p210Bcr-Abl. While p210Bcr-Abl is the hallmark of chronic myeloid leukemia (CML), p190Bcr-Abl occurs in the majority of Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients. In CML, p190Bcr-Abl occurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190Bcr-Abl and potential targeting therapies are largely uncharacterized. We employed next generation sequencing, phospho-proteomic profiling, and drug sensitivity testing to characterize p190Bcr-Abl in CML and hematopoietic progenitor cell line models (Ba/f3 and HPC-LSK). p190Bcr-Abl CML patients demonstrated poor response to imatinib and frequent mutations in epigenetic modifiers genes. In contrast with p210Bcr-Abl, p190Bcr-Abl exhibited specific transcriptional upregulation of interferon, interleukin-1 receptor, and P53 signaling pathways, associated with hyperphosphorylation of relevant signaling molecules including JAK1/STAT1 and PAK1 in addition to Src hyperphosphorylation. Comparable to p190Bcr-Abl CML patients, p190Bcr-Abl cell lines demonstrated similar transcriptional and phospho-signaling signatures. With the drug sensitivity screening we identified targeted drugs with specific activity in p190Bcr-Abl cell lines including IAP-, PAK1-, and Src inhibitors and glucocorticoids. Our results provide novel insights into the mechanisms underlying the distinct features of p190Bcr-Abl CML and promising therapeutic targets for this high-risk patient group.
引用
- Adnan-Awad S, Kim D, Hohtari H, et al. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2020. PMID: 33168949. doi:10.1038/s41375-020-01082-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。